At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 7 enrolled
Drug / intervention
MIB-626drug
Likely dose
MIB-626 500 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2a Study of NAD+ Precursor Supplementation in Friedreich's Ataxia
In Brief
A Phase 2 clinical trial evaluating MIB-626 for Friedreich Ataxia. Completed, enrolled 7 participants across 1 site.
Detailed Summary
The primary objective is to test the safety and tolerability of short-term therapy with a nicotinamide adenine dinucleotide (NAD+) precursor (MIB-626) in adults with Friedreich's Ataxia (FA) without overt heart failure and with a left ventricular ejection fraction ≥ 40%. A key secondary objective is to test the effects of MIB-626 on cardiac and skeletal muscle bioenergetics.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsFriedreich Ataxia
CountriesUnited States
CollaboratorsChildren's Hospital of Philadelphia
Timeline
Phase 2CompletedFinished
20222023202420252026
First PostedMar 2021
Enrollment StartMay 2021
Primary CompletionMay 2022
TodayJul 2026
First PostedMar 25, 2021
Enrollment StartMay 17, 2021
Primary CompletionMay 19, 2022
TodayJul 2, 2026
Enrollment to primary: 1.0 yearsPosted 5.3 years ago
Interventions
MIB-626drug
Two (2) 500 mg Tablets, By Mouth, Daily